KASID
- Who should continue the budesonide 2-mg foam treatment for up to week 6 in patients with mild-to-moderate distal ulcerative colitis?
- Published online: February 18, 2020
- 1,796 Views
- 10 Download
- 0 Crossref
- 0 Scopus
| Predictive factors for achievement of mucosal healing by budesonide 2-mg foam in ulcerative colitis: a pooled analysis of data from two clinical trials Toshifumi Hibi, Makoto Naganuma, Eisei Oda, et al. Intest Res. 2020;18(1):56-68. Topical therapy is recommended for the mild-to-moderate distal lesions of ulcerative colitis. Foam preparations have advantages of less leakage due to high retention than a liquid enemas and wider distribution than a suppository. The use of budesonide 2-mg foam (BF) twice-daily showed superiority for attaining mucosal healing (MH) after 6 weeks compared to placebo, however, inconvenient administration than that of oral medication may lead to low compliance of the patients. The present study analyzed the prognostic factors for mucosal healing at 6 weeks of BF treatment by a post hoc analysis of the pooled data from 2 clinical trials and intended to help determine the adequacy of treatment continuation. 
Best regards, |
- Related articles
-
-
Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study.
Naganuma M, Aoyama N, Tada T, Kobayashi K, Hirai F, Watanabe K, Watanabe M, Hibi T. J Gastroenterol. 2018;53(4):494-506
https://doi.org/10.1007/s00535-017-1376-4 -
Baseline oral 5-ASA use and efficacy and safety of budesonide foam in patients with ulcerative proctitis and ulcerative proctosigmoiditis: analysis of 2 phase 3 studies
Bosworth BP, Sandborn WJ, Rubin DT, Harper JR. Inflamm Bowel Dis. 2016;22(8):1881-1886
https://doi.org/10.1097/MIB.0000000000000860 -
Middle-term prognosis in patients with ulcerative colitis who achieved clinical and endoscopic remission by budesonide rectal Foam
Naganuma M, Hirai F, Kobayashi K, Watanabe K, Takeuchi K, Aoyama N, Nozawa H, Motoya S, Ohmori T, Harada A, Nagai Y, Abe T, Yamada Y, Inagaki K, Shimizu N, Kanai T, Watanabe M, ESCORT study Group. PLoS One. 2019;14(8):e0220413
https://doi.org/10.1371/journal.pone.0220413
-
Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study.
